Expression of trisomic proteins in Down syndrome model systems

Area of Science:

• Genetics
• Molecular Biology
• Neuroscience

Background:

• Down syndrome (DS) is the most common genetic cause of intellectual disability.
• DS results from trisomy of human chromosome 21 (HSA21), leading to gene dosage effects.
• Protein-level expression of HSA21 genes in DS is less understood than RNA-level expression.

Purpose of the Study:

• To quantify trisomic protein expression in Down syndrome (DS) using newly available antibodies.
• To investigate protein expression in DS lymphoblastoid cell lines (LCLs) and mouse models.
• To compare protein-level findings with existing RNA-level data for HSA21 genes.

Main Methods:

• Quantitative Western blotting was employed to analyze protein expression.
• Antibodies targeting 20 proteins encoded by HSA21 were used.
• Analysis was performed on LCLs from DS patients and brain tissue from two DS mouse models (Tc1 and Ts65Dn).

Main Results:

• Three proteins (CCT8, MX1, PWP2) showed elevated expression in DS LCLs.
• In the Tc1 mouse model, only SIM2 and ZNF295 proteins were elevated.
• In the Ts65Dn mouse model, only ZNF294 protein was elevated.
• Significant inconsistencies were observed between protein and mRNA expression levels.

Conclusions:

• Protein-level analysis reveals specific gene dosage effects for a subset of HSA21 genes in DS models.
• Discrepancies between RNA and protein levels highlight the complexity of gene regulation in DS.
• The developed antibody resources are valuable for future research into the molecular mechanisms of intellectual disability in DS.